If you follow peptides at all, 2026 is the year to watch. A scheduled FDA advisory-committee review could reshape which compounds licensed pharmacies are allowed to compound, and many of the peptides people ask us about are on the table.
How we got here
In 2023, the FDA restricted a group of peptides from compounding while it evaluated their safety. In 2026, the agency signaled a reconsideration and scheduled advisory-committee discussion, the formal venue where these questions are aired before any change.
What's at stake
At the July 23–24, 2026 meetings, the committee is set to review seven peptides — BPC-157, KPV, TB-500, MOTS-c, DSIP (delta sleep-inducing peptide), Semax, and Epitalon — for possible inclusion on the list pharmacies may compound. Five more (including GHK-Cu and Melanotan II) are slated for a separate meeting before the end of February 2027. Depending on how the review lands, some could move toward eligibility while others stay restricted. These are possibilities under discussion, not decisions — nothing is final until the FDA formalizes it through rulemaking.
What to watch
- Which specific peptides are addressed, and how.
- Whether the advisory committee's input becomes formal FDA guidance.
- How licensed pharmacies and providers respond once rules are clear.
We maintain a live countdown and a running feed on the 2026 Updates page, updated as real news lands rather than speculation.
Bottom line
2026 could be a turning point for peptide access, or it could move slowly. Either way, the responsible approach is to follow the actual decisions and work with a licensed provider, not to front-run the outcome with an online purchase.